Why This Matters
The Medicare GLP-1 Bridge Program, launched July 1, 2026, is a historic expansion of access. For the first time, eligible Medicare beneficiaries can access weight-loss GLP-1 medications at a $50 monthly co-pay, rather than the $500 to $1,300 list price. For many older Americans who are living with obesity and carrying the cardiovascular, joint, and metabolic consequences, this access is genuinely valuable.